Thermo Fisher Scientific Ataxin 2 Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 0.1–0.5 µg/mL
• Publications: [References not provided]

Immunohistochemistry (Paraffin) (IHC (P))

• Tested Dilution: 2–5 µg/mL
• Publications: [References not provided]

Product Specifications

Product Specific Information

Reconstitute with 0.2 mL of distilled water to yield a concentration of 500 µg/mL.

Target Information

The autosomal dominant cerebellar ataxias (ADCA) are a group of neurodegenerative disorders involving progressive degeneration of the cerebellum, brain stem, and spinal cord. ADCA is divided into three types (I–III).
Defects in the Ataxin 2 gene cause spinocerebellar ataxia type 2 (SCA2), belonging to ADCA type I, characterized by cerebellar ataxia with additional symptoms such as optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy, and dementia.
SCA2 results from expansion of a CAG repeat in the coding region; longer expansions lead to earlier onset. Alternatively spliced transcript variants exist, though full-length sequences are undetermined.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

제품 이미지

(관련 항원 구조 이미지 및 제품 이미지 포함)